


## HDAC-IN-38

<b>Cat. No.:</b>	HY-146351
<b>CAS No.:</b>	2408123-36-2
<b>Molecular Formula:</b>	C <sub>27</sub> H <sub>28</sub> ClN <sub>3</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	461.98
<b>Target:</b>	HDAC
<b>Pathway:</b>	Cell Cycle/DNA Damage; Epigenetics
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



## BIOLOGICAL ACTIVITY

<b>Description</b>	HDAC-IN-38 (compound 13) is a potent HDAC inhibitor. HDAC-IN-38 shows similar micro-molar inhibitory activity toward HDAC1, 2, 3, 5, 6, and 8. HDAC-IN-38 increases cerebral blood flow (CBF), attenuates cognitive impairment, and improves hippocampal atrophy. HDAC-IN-38 also increases the level of histone acetylation (H3K14 or H4K5) <sup>[1]</sup> .			
<b>IC<sub>50</sub> &amp; Target</b>	HDAC8 0.533 μM (IC <sub>50</sub> )	HDAC6 1.27 μM (IC <sub>50</sub> )	HDAC3 2.86 μM (IC <sub>50</sub> )	HDAC1 3.82 μM (IC <sub>50</sub> )
	HDAC5 6.27 μM (IC <sub>50</sub> )	HDAC2 6.62 μM (IC <sub>50</sub> )		

## REFERENCES

[1]. Kaur N, et al. Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment. Eur J Med Chem. 2020 Feb 1;187:111915.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA